Scientists at the National Institute of Neurological Disorders and Stroke (NINDS) seek patients with blepharospasm for a double-blind, placebo-controlled study of the drug mexiletine.
Eligible patients must have had their last botulinum toxin treatment at least 3 months prior to enrollment in the study, and must have a statement from their primary physician giving medical clearance including an EKG within the past 12 months. Patients with a history of cardiac disease are not eligible. Participants in the study will be asked to stop any medication that may interact with mexiletine.
The study will take place at the National Institutes of Health (NIH) Clinical Center in Bethesda, MD. All study-related expenses will be paid by the NIH.
For more information, contact Dr. Fiona Molloy at (301) 594-0937 or Dr. Kirsten Zeuner at (301) 402-3499.